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Meta-analysis has seen increasing use as a tool in epidemiology over the past five years. Although this method is relatively well accepted for use in
clinical trials, its use has proved somewhat more controversial in epidemiology. If meta-analysis is viewed as an evolutionary improvement over the
review article, it may become more widely acceptable. Meta-analyses should incorporate the concern for study quality and differences in study design
seen in classic review articles with the concern for rigor, objectivity, and quantitative precision characteristic of meta-analysis. Available tools for consid-
eration of differences among studies are described with several examples from the literature. The extent to which various methods are used in pub-
lished meta-analyses is described. Methods for assessing publication bias, and tools for combining dose-response data, are discussed also.
Evaluation of risk factors and protective factors for cancer must be based on the weight of the evidence. Tools such as meta-analysis are essential if
we are to interpret the vast number of completed studies in cancer epidemiology. - Environ Health Perspect 102(Suppl 8):61-66 (1994)
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Introduction
Improving our understanding of cancer
epidemiology requires new, more powerful
tools for evaluating the health effects of
exposures to possible carcinogens and anti-
carcinogens. Cancer epidemiologists often
encounter difficulty in obtaining samples
of sufficient size to detect the effect of
exposures. Noise in the data often obscures
the effect of those exposures. Meta-analysis
represents an important innovation for
increasing statistical power in epidemio-
logic studies.
Some epidemiologists seem to view
meta-analysts as a form ofintellectual parasite
who collects the hard work ofothers, extracts
a few numbers from each study, performs
some inappropriate calculations and takes
credit for the conclusions. Wherever one
places meta-analysts within the epidemio-
logic food web, they require a rich supply
of completed studies for sustenance. In
cancer epidemiology, the resources for
meta-analysis have been abundant. Table 1
lists the annual publication rate ofepidemi-
ologic studies listed in MEDLINE for various
types of neoplasms. This table demon-
strates a steady, almost monotonic increase
in the rate of publication in every area of
cancer epidemiology over the past 27 years.
Although meta-analysts are opportunis-
tic feeders, they have been somewhat slow
to take advantage of the niche available in
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cancer epidemiology. MEDLINE lists only 32
meta-analyses in cancer epidemiology, 28 of
which were published in the past three years.
The slow introduction and use ofmeta-
analysis in epidemiology in general and
cancer epidemiology in particular reflects
the difficulties associated with meta-analysis
in this context. The most extensive use of
meta-analysis in medical research has
involved clinical trials. The relative consis-
tency ofstudy designs and similarity ofout-
come measures has facilitated meta-analysis
in this area. Epidemiologic studies, on the
other hand, use a wide range ofstudy popu-
lations andmethods with avarietyofmeasures
of exposure and outcome. Consequently,
they are more difficult to combine and
meta-analysis is less well accepted in epi-
demiology than in clinical trials.
The Problem of Evaluating the
Weight ofthe Evidence
Evaluating a set of studies in cancer epi-
demiology that focuses on a specific risk
factor requires some method for combining
the results of these studies. Any method
must follow the general model described by
Equation 1, a simple, weighted average of
results.
Table 1. Average number of studies per year in cancer
epidemiology.
Year of publication
Site 1966-75 1976-82 1983-87 1988-92
Bladder 7 5 12 19
Colon 9 22 32 24
Breast 26 47 51 75
Prostate 3 4 5 8
Brain 11 9 11 15
Lung 28 27 47 55
Liver 9 14 17 18
Uterus 12 16 20 19
Total 109 152 201 245
Yw= xwiyiIxwi
wherey is the summary statistic from study
i, wi is the weight applied to study i, and
Yw is thepooled summary statistic.
The specific method used to determine
the weights and the method used to deter-
mine the level of confidence associated
with the pooled relative risk estimate differ-
entiates the methods used in combining
study results. These methods fall into two
broad categories, qualitative and quantita-
tive.
The classic review article takes the qual-
itative approach in determining what
weights to apply when combining study
results. Review articles generally do not
employ a strict protocol for identification
of all completed studies. Studies that are
not included are given an implicit weight
of zero. In evaluating studies that are
identified, the approach taken in most
review articles involves excluding or dis-
counting studies from consideration based
upon the perceived potential for bias and
confounding. Those studies felt to be
fatally flawed are given an implied weight
of zero. The remaining studies are com-
bined according to a vague, implicit
weighting scheme that tends to give greater
weight to large prospective studies based
upon the assumption of greater potential
for bias in retrospective studies. Review
articles usually conclude with an assertion
as to the presence or absence of a true risk
rather than a specific estimate of the rela-
tive risk of cancer. The emphasis in review
articles is on the validity ofindividual stud-
ies rather than the accuracy ofthe final risk
estimate.
A simple quantitative approach to pool-
ing study results emphasizes precision in
combining study results and relies on an
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assumption that the group ofstudies being
pooled represents a homogeneous set of
experiments. The simplest weighting
scheme gives a uniform weight of one to
every study. Uniform weighting reduces
Equation 1 to a simple, unweighted aver-
age. This is clearly inappropriate and unin-
formative. If the studies to be combined
are truly homogeneous, the best linear,
unbiased estimator of the true mean is
derived using weights based upon preci-
sion. Precision is expressed as the inverse of
the variance for the summary statistic. This
model is often referred to as the Peto
method for meta-analysis (1).
The homogeneity assumption in meta-
analysis gives rise to the most important
criticism of meta-analysis. Critics charge
that a meta-analysis is simply precision
masquerading as validity. In other words,
meta-analysis produces a single estimate of
relative risk with confidence intervals that
are substantially narrower than those in
any individual study. This suggests a great
improvement in precision, but may fail to
consider the importance ofvalidity in eval-
uating a group of studies. Some degree of
heterogeneity is inevitable when different
investigators use different methods and
study populations, despite the fact that
they may be exploring the same possible
causal relationship.
The classic review paper takes the
opposite approach, focusing on validity to
the exclusion ofprecision. The presumption
that weaknesses or potential weaknesses in
the design of individual studies should be
the overriding concern in combining study
results drives the conventional review. In
drawing a conclusion based on a qualitative
assessment ofindividual studies, the author
ofa review article conducts a crude form of
meta-analysis with a simplistic, unspecified
weighting protocol. As a consequence, the
reviewer sacrifices precision and scientific
rigor over a concern about the heterogene-
ity among studies.
Clearly, both ofthese extreme approaches
are flawed. A qualitative review article is
prone to bias and tends to be inefficient in
its use ofthe available data. A meta-analysis
that focuses on a single, numerical result
without careful consideration of the issues
ofvalidity and the factors that differentiate
the individual studies is inadequate and
open to misinterpretation. The ideal meta-
analysis combines the rigor of the purely
quantitative meta-analysis with the concern
for variations in study design exhibited in
review articles.
Meta-analysis and Its
Application in Cancer
Epidemiology
Any meta-analysis includes four compo-
nents: identification of a set ofcombinable
studies, extraction of summary data, pool-
ing of summary data, and delineation of
differences in study design with an evalua-
tion ofthe impact ofthose differences. Let
us consider each of these, paying careful
attention to the concerns raised above.
Study Selection and Publication Bias
The first step in any meta-analysis is the
identification ofan appropriate set ofstudies
for pooling. Although computerized litera-
ture searches have greatly facilitated this
process, they inevitably miss relevant pub-
lished studies. Inconsistencies in the use of
key words require broad, inclusive searches
with careful review ofidentified studies to
locate additional studies. The reference list
from each study should be checked to
identify as many ofthe pertinent published
studies as possible. A clearly defined protocol
should then be used to identify studies
appropriate for meta-analysis.
The problem of unpublished studies
creates a potential for bias with no simple
solution. If a decision on the part of a
researcher to submit a study for publica-
tion or a decision on the part of a journal
to accept a publication is influenced by the
direction of the study results, a bias is
introduced. This systematic failure by
investigators or journals to publish studies
is referred to as "publication bias." Although
publication bias has been amply demon-
strated for clinical trials (2), it has not
been systematically investigated for epi-
demiologic studies. The potential for bias
in cancer epidemiology is arguably high.
Case-control studies may investigate a wide
range ofhypotheses. The lack of a strong
incentive to publish negative results from
these studies may lead to publication bias.
One approach that has been advocated
to minimize bias is the registration of
ongoing epidemiologic studies (3). A com-
prehensive registry ofepidemiologic studies
should help to minimize publication bias. A
registry ofstudies in cancer epidemiology
has been initiated by the International
Agency for Research on Cancer (DM
Perkins, personal communication). The
success ofthis registry will help determine
ifthis approach is feasible.
In the absence ofa registry ofepidemi-
ologic studies, it is difficult, ifnot impossi-
ble, to quantify publication bias. It is
possible, however, to get some insight as to
the presence or absence ofpublication bias.
One can reasonably assume that larger and
consequently more expensive studies are
less likely to go unpublished than smaller,
less precise studies. A plot of published
study results as a function ofsome measure
of the precision of the results (e.g., stan-
dard error of the log relative risk) should
yield a funnel-shaped scatter plot with a
decrease in the scatter ofresults as precision
increases (4). A truncation of the lower
halfof the funnel would imply that small
negative studies had not been published.
Figure 1 shows an example ofa funnel
plot constructed using data from a study of
colorectal cancer and alcohol consumption
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Figure 1. A funnel plot for epidemiologic studies of alcohol consumption and colorectal cancer.
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(5). This plot is somewhat truncated, sug-
gesting a degree ofpublication bias. In fact,
ifwe divide these studies according to ter-
tile of precision, the relative risk drops
from 1.35 to 1.15 to 1.08 with increasing
precision. This suggests that some publica-
tion bias may exist for the smaller, less pre-
cise studies. Begg and Mazumdar (6) have
recently proposed a method for detection of
publication bias using an adjusted rank cor-
relation test that represents a statistical ana-
log ofthe funnel plot.
One can also estimate the possible
impact of publication bias on a specific
meta-analysis. Calculation of the size ofa
negative study that would be required to
increase the probability ofa Type I error to
a level considered nonsignificant will pro-
vide an estimate of the extent of publica-
tion bias necessary to invalidate the
conclusions ofa meta-analysis. Sugita et al.
(7) have proposed a method that infers the
magnitude of missing studies based upon
an assumed distribution of study results
and adjusts the meta-analysis accordingly.
Data raction
A meta-analysis requires the abstraction of
comparable measures ofrisk along with the
variance associated with the summary sta-
tistic for risk from each study. Again, the
variability among studies poses a problem
for the meta-analyst. Risk estimates may
come in many forms, including odds ratios
and relative risks from binary exposure data
or logistic regression coefficients from con-
tinuous exposure measures. Outcomes may
include mortality, a wide range ofindicators
ofmorbidity, or biomarkers for subclinical
disease.
Perhaps the most difficult task of an
epidemiologic meta-analysis is to determine
comparable measures of exposure among
studies. The meta-analyst must make deci-
sion based upon knowledge ofthe relevant
epidemiology to determine which summary
statistics are comparable.
Determination ofweights for meta-
analysis depends upon extraction ofvariance
estimates. Many studies do not provide
variance estimates and some do not provide
sufficient statistics for calculating variance
estimates. Calculation of variances from
confidence intervals orp values is relatively
straightforward. Often, however, particu-
larly in older studies, one must reconstruct
the original data to calculate variances.
Occasionally, even this is not possible, and
the original data must be sought from the
investigator.
Some investigators choose to pool data
rather than summary statistics and analyze
the results as if they were the product of
one large study. This approach is inappro-
priate unless the authors specifically
account for the effects of the differences
among studies in their analysis. One could
argue that this is not, in fact, a true meta-
analysis, since a meta-analysis, by definition,
involves combining the results of multiple
studies.
Many judgments are made in the selec-
tion and rejection ofpapers, the evaluation
ofstudy quality, and the extraction ofdata
in the process of meta-analysis. Persons
extracting data from individual studies must
follow a strict protocol that is clearly
defined in advance. Observer errors, occa-
sionally the result ofbias, can be reduced by
arranging for all decisions and data extrac-
tion to be done by two independent investi-
gators with differences settled by conference
and, ifnecessary, by a thirdparty.
PoolingofStudyResults
Although the term meta-analysis often is
used to refer only to the computational
synthesis ofresults, these calculations tend
to be the most straightforward and least
time consuming aspect ofthe entire proce-
dure. Nonetheless, the specific method
chosen may affect a study's conclusions (8).
Several methods are available for pooling
results. Each method calculates a weighted
average of the relative risk estimates from
the original studies. The assumptions
underlying the meta-analysis determine the
weights to be used in the calculation.
These assumptions relate, in part, to the
degree ofheterogeneity among studies and
the sources of that heterogeneity. Study
results differ as a consequence ofwithin-
study variation and among-study variation.
Within-study variation reflects variability
in response for subjects investigated
according to a single study design. The
homogeneity assumption implies that vari-
ation among subjects is the primary source
ofvariation. Among-study variation arises
from differences in protocol among studies.
These interstudy differences represent the
consequences of fixed and random effects
on subject response.
The Peto method (1) requires an
assumption ofhomogeneity. Although it
provides a test for the validity of this
assumption, it does not provide any adjust-
ment to account for that heterogeneity.
This is the most widely used method for
pooling studies in cancer epidemiology.
Although the assumption ofhomogeneity
is convenient, it is not entirelyvalid.
Use of the random effects model in
pooling study results provides a purely
quantitative method ofallowing for hetero-
geneity. The best known implementation
of the random effects model for meta-
analysis was developed by Dersimonian
and Laird (8). The Dersimonian and Laird
(D&L) method uses Cochran's Qand delta
statistics to evaluate and adjust for hetero-
geneity in the variance among studies and
is therefore referred to occasionally as the
Cochran, Dersimonian, and Laird method.
In calculating the weights for Equation 1,
the random effects model adds a random
component to the variance estimates before
taking their inverse.
Q=Xw (yi y)2, [2]
where Q is Cochran's statistic for hetero-
geneity and
y=xwI.y./ w. Yw x I I [3]
is the pooled estimate based on the
assumption ofheterogeneity with weights
given by
w(2 )-l )[4]
where S2 is the variance ofthe relative risk
estimate for study i.
The expected value of Qis given by the
equation
E(Q) =(k-l)+1 (Xwi-wIXwi), [5]
where the random component ofvariance
a, is defined as
m{ (wi-wi2IXwi)}
[6]
The net effect of the D&L model is to
decrease the weight on the most precise
estimates ofrelative risk and to increase the
variance associated with the pooled esti-
mate ofrelative risk. Although this method
addresses the question of heterogeneity
mathematically, it does not deal directly
with the problem ofidentifying the source
ofvariation among studies. A meta-analysis
that simply presents the pooled result of a
group of studies without considering the
impact of differences in study design on
relative risk estimates represents a misuse of
this method.
Many epidemiologic studies consider
exposure in the form of a dichotomous
variable. The summary result for these
studies is an estimate of the relative risk
associated with exposure. Often, however,
the researchers will evaluate a dose response
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relationship. Pooling dose response data
will help determine if a causal link exists
between the exposure and cancer. Greenland
and Longnecker (9) describe a method for
pooling the coefficients from dose-response
relationships. This is developed further by
Berlin, Longnecker, and Greenland
(unpublished data).
Meta-analysis, in addition to improving
our ability to identify small but significant
relative risks in the context of inconsistent
research findings, enhances our capacity to
interpret negative results. When a meta-
analysis yields nonsignificant results, an
analysis of the potential for type II error
associated with these results can provide
useful insight into the need for additional
studies.
Table 2 lists the results from a recent
meta-analysis (9) ofseven case-control and
cohort studies that investigated the associa-
tion between exposure to chlorination by-
products in drinking water and cancer. The
right side of the table lists, the results of
power calculations for the nonsignificant
studies. These results help determine ifthe
lack of significance associated with one
cancer site represents a true lack ofassocia-
tion, or a lack of statistical power. For
example, these results suggest that exposure
to chlorination by-products does not sub-
stantially increase the risk of lung cancer;
but the available data clearly do not pro-
vide adequate power to reject the hypothe-
sis of a small increase in the risk for brain
cancer as a consequence of exposure to
chlorination by-products.
Evaluation ofBias andConfounding
Heterogeneity among study results arises as
a consequence of differences in study
design that have not been accounted for.
Confounding, interaction, and bias
account for differences in results among
studies, which are not due to chance. (Ifwe
accept that biologic mechanisms are deter-
ministic, all differences among study results
reflect a failure to account fully for the
entire spectrum of causal factors.) The
thorough, well-conceived meta-analysis will
attempt to use available statistical tools to
evaluate and, to the extent possible, quantify
those factors that contribute to heterogene-
ity among studies. Several approaches are
available.
Under ideal conditions, the impact of
specific biases and confounders would be
known with some precision and could be
quantified. This information would allow
for the quantitative adjustment ofrisk esti-
mates before pooling. Unfortunately, the
data needed to determine the correct
Table 2. Site-specific meta-analysis with power calculations for the association of chlorianted drinking water with
cancer.a
Powerb for detection of specified
Relative _ relativerisks(a=0.05)
Site nc risk estimate 95% confidence limits p 1.20 1.40 1.60
Bladder 7 1.21 1.09 1.34 <0.0001 _d
Brain 2 1.29 0.53 3.14 0.56 0.02 0.04 0.07
Breast 4 1.18 0.90 1.54 0.24 0.04 0.25 0.62
Colon 7 1.11 0.91 1.35 0.32 0.18 0.34 0.75
Colorectal 8 1.15 0.97 1.37 0.10 0.32 0.61 0.96
Esophagus 5 1.11 0.85 1.45 0.43 0.08 0.39 0.76
Kidney 4 1.16 0.89 1.51 0.23 0.05 0.30 0.67
Liver 4 1.15 0.94 1.40 0.16 0.06 0.50 0.91
Lung CA 5 1.01 0.86 1.18 0.94 0.57 0.98 >0.99
Pancreas 6 1.05 0.91 1.22 0.48 0.43 0.97 >0.99
Rectum 6 1.38 1.01 1.87 0.04 - - -
Stomach 6 1.14 0.94 1.38 0.19 0.08 0.56 0.93
aFrom Morris et al. (9). bPower is defined as 1-,B where P is the probability of Type II error at the given levels of
true relative risk (RR) and significance. CNumber of studies evaluating specific cancer site. dStatistical power was
not calculated ifthe meta-analysis was significant.
adjustment are the same data included in
the specific meta-analysis. Consequently,
quantitative adjustment for confounding
and bias creates an impression of precision
that is not entirelyvalid.
The meta-analyst can draw on several
tools in an effort to evaluate the factors that
contribute to heterogeneity in study results.
These tools are similar to those used to
evaluate confounding, interaction, and bias
within the context of a single experiment
amd include stratification, meta-regression,
sensitivity analysis, and qualityscoring.
Stratified analysis is the most common
tool in meta-analysis for evaluating study
heterogeneity. With studies grouped based
upon differences in study design, the inves-
tigator can pool the groups separately to
determine if these differences (e.g., adjust-
ment for a specific confounder) have an
impact on relative risk estimates. Table 3
shows an extensive stratified analysis from a
meta-analysis of oral contraceptives and
breast cancer (10).
Ifthe studies differ according to a con-
tinuous or ordinal independent variable,
meta-regression may be appropriate. As
described by Greenland (11), this method
allows for evaluating the association
between study results and a covariate using
weighted least squares regression tech-
niques based on the general relationship:
ln(R)=Bo+B1M1 +e, [7]
where R is the relative risk, Bo is the base-
line risk, M1 is the effect modifier with
coefficient BI, and e is an error term. Both
the effect and effect modifiers are weighted
by the reciprocal of the variance for each
study. This can be readily extended to a
multivariate model.
Meta-regression could be used, for
example, in the meta-analysis ofa group of
studies investigating associations between
air pollution and lung cancer. To test the
hypothesis that relative risk estimates might
be influenced by the altitude ofthe city in
which the study was conducted, the meta-
analyst could include altitude in a meta-
regression of these results. As in single
experiments, regression is a more powerful
tool than simple stratification. Unfor-
tunately, use ofmeta-regression often is not
feasible and the meta-analyst must resort to
stratification.
Sensitivity analysis, a third tool for eval-
uating the impact ofstudy heterogeneity on
study results, has seen limited use in meta-
analysis. If the presence of bias or con-
founding is suspected in a study or group of
similar studies, the analyst can simulate the
impact of a various levels of bias or con-
founding on study results. By simulating
the relationship between confounding or
bias and study results, the appropriateness
of ignoring the effect of concern can be
evaluated. Table 4 shows the results of a
sensitivity analysis based upon various
degrees of assumed confounding from a
study that evaluated the association of
smokingwith cervical cancer (12).
Ultimately, there is likely to be a variety
of factors affecting study results that are
extremely difficult to quantify. Nonethe-
less, experience tells us that some study
designs are more prone to bias than others.
Authors ofconventional review articles use
implicit subjective criteria to evaluate dif-
ferences in study design and determine the
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Table 3. Stratification analysis from a meta-analysis of breast cancer and oral contraceptives.' Summary relative
risk (RR) estimates among case-control and follow-up studies for different characteristics of oral contraceptive (OC)
use.
Random effect model
Summary estimates Test forhetero_geneity
Characteristics of OC use RR (95% Cl) X2 p
Case-control studies
Any OC use
All studies 1.06 (0.98-1.14) 50.62 0.005
Cases accrued after 1975 1.08 (0.99-1.18) 44.71 0.005
Cases accrued after 1980 1.06 (0.93-1.21) 23.52 0.009
Premenopausal cases onlyb 1.17 (0.95-1.45) 13.77 NS
Duration of OC use
< 1 year 0.97 (0.83-1.14) 20.24 0.027
. 10 years 1.14 (0.90-1.42) 15.70 NS
. 10 years (cases accrued after 1980) 1.22 (0.91-1.63) 13.30 0.037
Duration of OC use before first full-term pregnancy
<1 year 1.07 (0.78-1.47) 5.55 NS
.4 years in women < 45 years old 1.72 (1.36-2.19) 11.69 NS
.4 years in women < 45 years old 1.73 (1.29-2.33) 8.86 NS
(cases accrued after 1980)
Time since first OC use
2 12 years 1.08 (0.95-1.22) 22.71 0.01
Family history of breast cancer
Yes 1.14 (0.67-1.96) 2.77 NS
No 1.44 (1.09-1.88) 3.49 NS
Follow-up studies
Any OC use 1.06 (0.92-1.22) 6.51 NS
NS, Not significant. aFrom Romieu et al. (10). bFor the purposes of this analysis,
age < 45 years.
unstated weighting criteria for epidemio-
logic studies. The goal ofquality scoring in
meta-analysis is to develop an explicit,
objective scoring criterion to allow for
quantification ofthe major components of
study quality.
Quality scores provide a ranking system
for the studies based upon methodology
and the potential for bias and confound-
ing. Although quality scoring has been
used extensively in meta-analyses ofclinical
trials, no well-defined protocol exists for
quality scoring ofepidemiologic studies. A
variety ofquality scoring systems has been
developed for epidemiologic meta-analysis
(5,13,14). Two studies have demonstrated
associations between relative risks and
quality scores (1,14).
Summary and Conclusions
In the past 26 years, more than 4000 studies
have been published in cancer epidemiol-
ogy. Identification of cancer risk factors
depends upon our ability to distill the
results of these studies in a meaningful
way. The traditional method for evaluating
a group ofstudies, the review article, does
not aspire to the same standards of sci-
entific objectivity seen in the original epi-
demiologic studies. In some respects, a
review article is simply a crude meta-analysis
premenopausal was defined as
that does not specify or follow a rigorous
protocol in selecting or combining study
results.
In using a rigorous protocol, a meta-
analysis reduces the potential for bias pre-
sent in review articles. Quantitative
procedures for combining results also mini-
mize the potential for bias while making
the maximum use of information in the
original studies. Although a meta-analysis
can estimate a relative risk with far more
precision than the individual studies it con-
tains, that precision should not be mistaken
for validity. The challenge for meta analysts
is to fully consider differences in study
design while taking advantage ofthe positive
attributes ofmeta-analysis.
Qualitative review articles also may
include evidence from outside of the epi-
demiologic literature. Extending meta-
analysis to fully consider the weight ofthe
evidence demands some effort to include
the findings from nonepidemiologic litera-
ture, particularly toxicologic studies, as
appropriate. This information can assist in
evaluating the likelihood ofa causal associ-
ation based upon the issue of biological
plausibility.
Table 5 lists the methods used in 19
published meta-analyses ofcancer epidemi-
ology. Of these, the majority used pooling
Table 4. Sensitivity analysis from a meta-analysis of
cervical cancer and cigarette smoking.' Summary of
the results of graphical and variance-based meta-
analyses and sensitivity analysis.b
Graphical Variance-based
Sensitivity meta-analyses meta-analyses
analysis OR (95% Cl) OR (95% Cl)
No confounding
Never smoked 1.00 1.00
Former smoker 1.18 (0.98-1.42) 0.98 (0.80-1.21)
Current smoker 1.81 (1.54-2.12) 1.69 (1.50-1.91)
Low degree of confounding (10%)
Never smoked 1.00 1.00
Former smoker 1.06 (0.90-1.25) 0.88 (0.73-1.06)
Current smoker 1.63 (1.41-1.88) 1.52 (1.36-1.69)
High degree of confounding (30%)
Never smoked 1.00 1.00
Former smoker 0.83 (0.73-0.95) 0.69 (0.60-0.80)
Current smoker 1.27 (1.14-1.42) 1.18 (1.09-1.28)
"From Licciardone et al (12). bSensitivity analysis was
used to address the degree to which the unadjusted
ORs may have overestimated the true ORs becuase of
unmeasured confounding variables.
ofdata to combine results. Only four used
the D&L method. Stratification analysis
was commonly used to evaluate the impact
of differences in study design on results.
Few of the studies evaluated the impact of
potential biases and only four used quality
scoring. Adoption of newer methods in
meta-analysis together with more wide-
spread use ofexisting methods should yield
higher quality meta-analyses.
Meta-analysis provides an evolutionary
advance over the conventional review article.
Ongoing efforts to improve meta-analysis
will be required if it is to become widely
used and accepted as a tool in cancer epi-
demiology. Many of the existing problems
in meta-analysis involve the inadequate
capability to consider differences in study
design and study quality. A meta-analysis
must take into consideration the strengths
and weaknesses of the literature while
employing an explicit, objective, and quan-
titative methodology for pooling these
Table 5. Methods used in 19 published meta-analyses
in cancer epidemiology.
Combining results
Data pooling 8
Peto method 7
Dersimonian and Laird 5
Dose-response 4
Evaluation of confounding
Stratification 14
Sensitivity 1
Evaluation of bias
Quality scoring 4
Stratification 2
Sensitivity 3
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studies. This approach to combining stud-
ies helps to minimize the impact of the
biases ofa particular reviewer on the inter-
pretation of available studies. Overall, we
must develop approaches to considering
the weight ofthe evidence that employ the
most rigorous methods available for mini-
mizing bias while making the most
efficient use ofall available data.
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